Navigation Links
Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
Date:4/1/2013

CARLSBAD, Calif., April 1, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the publication of new data in the journal Circulation Research [doi:10.1161/CIRCRESAHA.111.300367] demonstrating that antisense targeting of apolipoprotein C-III (apoC-III) resulted in significant reductions in apoC-III and triglycerides, each an independent risk factor for cardiovascular disease.  Hypertriglyceridemia is a serious medical condition associated with premature coronary artery disease and an increased risk for pancreatitis.  Isis is developing its antisense apoC-III inhibitor, ISIS-APOCIIIRx, for the treatment of patients with severe hypertriglyceridemia and plans to report top-line data in the middle of this year. 

"Patients with high triglycerides and high apoC-III levels are at significant risk of developing cardiovascular disease, metabolic syndrome, diabetes and pancreatitis.  Despite currently available triglyceride-lowering agents, many patients cannot reduce their triglycerides to acceptable levels.  Because apoC-III is a key regulator of triglyceride clearance from the blood and itself is an independent risk factor for cardiovascular disease, lowering both apoC-III and triglycerides could provide significant therapeutic benefit," said Richard Geary , Ph.D., senior vice president of development at Isis.  "In this paper, we report consistent activity of antisense inhibition of apoC-III to lower both apoC-III and triglycerides in multiple rodent models of dyslipidemia, in non-human primates and in man.  These data support the potential therapeutic benefit a selective apoC-III inhibitor could offer patients with hypertriglyceridemia and elevated apoC-III.   Following the completion of the Phase 2 study, we plan to move rapidly into a Phase 3 study in the most severe patients with triglyceride levels greater than 880 mg/dL who are unable to reach acceptable triglyceride levels with currently available treatments."

In the published data, treatment with an antisense compound targeting apoC-III produced a variety of potential cardio-protective effects including significant dose-dependent reductions of apoC-III and triglycerides in all models and species, including man.  In addition, treatment with an antisense compound targeting apoC-III resulted in enhanced triglyceride clearance from blood following a high-fat meal, reduction of VLDL particles and a slight increase in HDL-C levels.  In all models and in the Phase 1 study, antisense inhibition of apoC-III was well tolerated.  These data were consistent across multiple preclinical models and species and in a Phase 1 study in healthy volunteers demonstrating that Isis' antisense technology was able to produce predictable and consistent responses among different animal models that translate into corresponding activity in man. In the Phase 1 study, treatment with ISIS-APOCIIIRx was well tolerated and produced rapid, dose-dependent median reductions of up to 44 percent in plasma triglycerides and up to 78 percent in apoC-III protein, with two out of the three subjects in the highest dose group achieving undetectable levels of apoC-III. 

ABOUT ISIS-APOCIIIRx
ISIS-APOCIIIRx inhibits the production of apoC-III, a traditionally 'undruggable' target that inhibits the clearance of triglycerides from the blood. People who do not produce apoC-III have lower levels of triglycerides and lower instances of cardiovascular disease. ApoC-III is elevated in patients with dyslipidemia, or an abnormal concentration of lipids in the blood, and is frequently associated with multiple metabolic abnormalities, such as insulin resistance and/or metabolic syndrome. In human population studies, lower levels of apoC-III and triglycerides correlated with a lower rate of cardiovascular events.

ABOUT HYPERTRIGLYCERIDEMIA
Hypertriglyceridemia can be caused by genetic defects, diet, obesity and uncontrolled diabetes and can lead to serious health problems, including cardiovascular disease and pancreatitis.  Triglycerides are an important measure of heart health and are routinely measured along with LDL-cholesterol and HDL-cholesterol.  Triglyceride levels of less than 150 mg/dL are considered within a normal range, and the American Heart Association recommends that a triglyceride level of less than 100 mg/dL is optimal.  Triglyceride levels of greater than 500 mg/dL are considered very high and levels greater than 1,000 mg/dL are considered to be severely high.  In these patients, diet and exercise have limited therapeutic benefit.  Patients with severely high triglycerides are at a higher risk of developing pancreatitis, a painful and sometimes fatal disease that requires hospitalization and close monitoring.  Based on prevalence data, Isis estimates there are greater than 200,000 patients with severely high triglycerides in the United States and Europe despite currently available therapies.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the discovery, development and potential for drugs for cardiovascular diseases, and the development activities, therapeutic and commercial potential and safety of ISIS-APOCIIIRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
2. Bloomberg BNA Publishes Sixth Edition of False Claims Act Treatise
3. MD+DI, the Global MedTech Authority, Publishes One-of-a-Kind Study with ITG Market Research on the Medical Device Outsourcing Landscape
4. Specialty Pharmacy Association of America (SPAARx) Publishes Definition of Specialty Pharmacy
5. Camfil Farr Publishes FAQ on HEPA Air Filters
6. French Lifestyle Secret Finally Revealed: Lycotec Publishes Unexpected Findings on Roquefort Cheese
7. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
8. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
9. Express Scripts Publishes Inaugural Drug Trend Quarterly, Provides First Comprehensive Overview of U.S. Prescription Drug Spending for 2012
10. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
11. Varian Medical Systems Publishes 2012 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Direct-to-consumer digital marketing ... and 65% increase in consumable sales, quarter-over-quarter ... DRIO ), a leader in digital health ... Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, ... and minimally invasive smart diabetes management solution. ...
(Date:1/23/2017)... plc, (NYSE: AGN ), a leading global pharmaceutical ... Academy (IHA). Designed to inspire a long-term commitment to Headache ... three-day, intensive overview on research and treatment options. This is ... since the inception of IHA in North America ... in 2014. "Allergan is dedicated ...
(Date:1/23/2017)... 2017  Using Astute Medical,s NephroCheck Test ... acute kidney injury (AKI) after open-heart surgery and ... guidelines significantly improved outcomes by reducing the ... 33 percent, according to a study ... Care Medicine. Experience the interactive ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue ... three-year outcome study on how outdoor behavioral healthcare (OBH) – also known as wilderness ... interpersonal difficulties while experiencing an increased sense of purpose both during and after treatment. ...
(Date:1/24/2017)... ... January 23, 2017 , ... During the January ... Carol Francis, Psychologist in the South Bay area , explained “Watching Women’s Marches ... people and by all people shines as a bright beacon of determination and ...
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania ... domain address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found ... along with its redesigned and retooled website. The treatment center has also revamped ...
(Date:1/23/2017)... ... 23, 2017 , ... Ultimate Medical Academy today announced the ... held March 23-25, 2017 in Tampa, and reminded educators and education leaders to ... include Dr. Michelle R. Weise, executive director of the Sandbox Collaborative, the R&D ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
Breaking Medicine News(10 mins):